NYU Langone


 

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resected HR-Melanoma: Efficacy & Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial

326 views
May 9, 2023
0 Comments
Login to view comments. Click here to Login
Videos